Yamadin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yamadin

Property Description
Active ingredient Famotidine
Primary Form Oral Tablet / Suspension
Pharmacological Class Histamine H₂-receptor antagonist
General Purpose Reduction of gastric acid secretion
Origin Synthetic compound

What Type of Medicine is Yamadin (Famotidine)?

Yamadin is a trade name for a medicine containing the active substance Famotidine, a specific chemical compound classified pharmacologically as a Histamine H₂-receptor antagonist (or H₂-blocker). This synthetic small molecule belongs to the therapeutic class of Gastrointestinal Agents. Famotidine's role as a potent and selective H₂-blocker is clinically recognized and supported by extensive pharmacological studies. The drug is typically administered as an oral tablet or a liquid oral suspension, although the active ingredient is also formulated as a sterile solution for intravenous injection for use in clinical settings. The medicine is most frequently supplied as a single-ingredient product, containing only Famotidine alongside necessary pharmaceutical excipients.

What is the Primary Purpose of Famotidine?

The primary purpose of Famotidine is the reduction of gastric acid secretion, which is achieved through a specific antisecretory action. This action involves the competitive inhibition of the H₂ receptors found on the stomach's acid-producing cells, effectively preventing the chemical signal that triggers acid formation. This mechanism is crucial for controlling acidity; this action leads to a marked decrease in the overall volume and acidity of gastric secretions. This confirmed control over stomach acidity is the central benefit, making the drug useful for relieving common symptoms such as heartburn and indigestion associated with excess stomach acid production. A typical scenario for its use involves managing the occasional discomfort resulting from rich or late evening meals, ensuring a targeted intervention within the digestive system.

Regulatory References

  1. National Library of Medicine (NIH)

What side effects are possible with Yamadin?

Possible Side Effects and Safety Information

The safety profile of Yamadin (Famotidine) is classified according to regulatory documents based on the frequency and the physiological system affected. The majority of documented adverse reactions are categorized as Common or Uncommon.

Frequency Classification of Adverse Reactions

The officially documented Common side effects typically involve the nervous system, such as headache and dizziness, or the gastrointestinal system, including constipation and diarrhea. Adverse reactions classified as Uncommon include fatigue, rash, taste disorder, and abdominal discomfort.

System-Organ Class Involvement

Adverse reactions classified as Very Rare in regulatory documents involve several system-organ classes, including blood and lymphatic system disorders (such as agranulocytosis and thrombocytopenia), and immune system disorders, specifically severe hypersensitivity reactions like anaphylaxis. Severe dermatological reactions, including Stevens-Johnson syndrome and Toxic epidermal necrolysis, are also documented as Very Rare serious events.

Population-Specific Safety Considerations

The official labeling notes specific safety considerations for certain patient populations. Individuals with impaired renal function (kidney disease) and older adults are explicitly documented as having an increased risk of developing Central Nervous System (CNS) adverse reactions, such as confusion or disorientation. Furthermore, a key safety constraint is that symptomatic improvement during therapy does not preclude the presence of an underlying gastric malignancy, as stated in regulatory guidelines.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents emphasize that the ingestion of Yamadin (Famotidine) in quantities exceeding the recommended dose requires immediate medical attention. Overdose is formally documented to involve potentially severe manifestations affecting the Central Nervous System (CNS) and the cardiovascular system.


Documented Overdose Manifestations

System Documented Clinical Signs
Central Nervous System Confusion, delirium, agitation, hallucinations, seizures (convulsions), and lethargy.
Cardiovascular Cardiac arrhythmias and QT prolongation, particularly with high exposure.

Official Emergency Requirements

Seeking Help: Individuals must seek immediate medical attention or call emergency services right away if a massive overdose is suspected or if severe symptoms, such as seizures or unresponsiveness, occur. Authorities explicitly mandate contacting a national poison control helpline for professional guidance.

Management: Treatment for famotidine overdose is symptomatic and supportive, as no specific antidote is known according to regulatory statements. Procedures such as gastric lavage or the administration of activated charcoal may be considered to limit further drug absorption.

Special Considerations: The official prescribing information notes an increased risk of severe CNS adverse reactions and cardiac effects in elderly patients and those with moderate to severe renal impairment.

Therapeutic Uses of Yamadin

Quick Facts

  • Therapeutic Role: May offer support for various gastrointestinal conditions related to excessive acid production.
  • Key Applications: Used in the management of duodenal ulcers and gastric ulcers.
  • Additional Uses: Employed in the care plan for gastroesophageal reflux disease (GERD) and pathological hypersecretory conditions.

What Yamadin Treats: Main Uses and Benefits

Yamadin is a medication utilized in therapeutic regimens to address symptoms associated with several gastric conditions. Its primary function is to modulate the volume of gastric acid secretions, which contributes to relief for individuals with digestive tract concerns.

The medication is frequently applied in the management of active duodenal ulcers and active gastric ulcers. It is also a component of maintenance therapy to aid in the reduction of recurrence of duodenal ulcers following initial healing.

Furthermore, Yamadin is an established therapeutic option for gastroesophageal reflux disease (GERD), including the care of related erosive esophagitis. It is also used to address the effects of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, where the stomach produces an unusually large amount of acid.

Eligibility and Restrictions for Use

Contraindicated Populations

The use of Yamadin is contraindicated in patients with a known history of serious hypersensitivity reactions, such as anaphylaxis, to Famotidine or to any other Histamine H₂-receptor antagonist medicine. Furthermore, specific injection formulations containing benzyl alcohol are prohibited for use in neonates due to the risk of toxicity.

Age- and Organ-Function Eligibility

Adults (17 years and older) are the fully eligible population for labeled indications. Pediatric use is conditional, established primarily for children one year of age and older for certain conditions, while use in infants remains limited or not established. Conditional eligibility also applies to patients with moderate to severe renal impairment (creatinine clearance less than 50 mL/min). In this group, the medicine is not recommended under standard conditions, requiring adjustment due to the risk of adverse effects.

Condition Preclusion and Physiological States

Evaluation for concurrent gastric malignancy is a mandatory pre-treatment eligibility condition for adults with gastric symptoms. For pregnant women, use is conditional and only recommended if clearly needed. The medicine is not recommended for use by lactating women, as the active ingredient is excreted into human milk, necessitating a decision to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

The official regulatory information for Famotidine (Yamadin) describes interaction patterns centered on two primary effects: the modification of gastric pH and the modulation of drug clearance. These interactions determine specific co-administration restrictions.

Interaction Scope

Property Value (Strictly Regulatory)
Medicinal product categories with documented interactions Acid-Dependent Drugs (Antifungals, HIV Antivirals), Tyrosine Kinase Inhibitors, Renal Transporter Inhibitors, Antacids, Gastric Mucosal Protectants.
Specific interacting medicines (if explicitly listed) Ketoconazole, Itraconazole, Erlotinib, Dasatinib, Probenecid, Tizanidine, Sucralfate, Antacids.
Mechanistic basis of interactions Pharmacokinetic: Increased gastric pH (alters drug absorption). Pharmacokinetic: Inhibition of renal tubular secretion (by Probenecid via OAT1/OAT3). Pharmacokinetic: Minor inhibition of CYP1A2 (Tizanidine).
Timing-based interaction rules Sucralfate must not be administered within 2 hours of Famotidine. Antacids must be taken 1 to 2 hours after Famotidine.
Population-specific interaction notes Renal Impairment: Clearance is slower, leading to increased plasma concentration and a need for dose reduction or extended dosing interval.
Interaction-related restrictions Co-administration with Probenecid is advised against due to a significant increase in Famotidine exposure. Co-use with acid-dependent Tyrosine Kinase Inhibitors is not recommended due to decreased TKI plasma concentration.

Interaction Classifications (High-Level)

Property Value (Strictly Regulatory)
Interaction severity classification Avoid/Not Recommended (e.g., Probenecid, Acid-Dependent TKIs). Significant Alteration of Exposure (e.g., Antifungals). Required Timing Separation (e.g., Sucralfate).
Regulatory basis U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) documentation.

Resulting Interaction Structure

The regulatory profile is defined primarily by pharmacokinetic interactions where the elevation of gastric pH causes a reduction in the absorption and subsequent plasma exposure of several co-administered acid-dependent drugs. A crucial constraint is the use of Probenecid, which impairs Famotidine's clearance via renal transporters, resulting in a marked increase in Famotidine concentration. The official documentation establishes these two main axes of risk: altered absorption and impaired clearance.

Mechanism of Action

Selective Blockade of the Histamine H2-Receptor

Famotidine acts as a highly selective competitive antagonist that directly binds to the Histamine H2-receptors located on the gastric parietal cells. This interaction prevents the endogenous messenger, histamine, from activating the receptor, thereby initiating the mechanism to interrupt the histamine-mediated signal that promotes acid secretion.


Downregulation of the Intracellular cAMP Signaling Cascade

The H2-receptor blockade modifies the early molecular steps inside the cell. By preventing receptor activation, Famotidine interrupts the subsequent signal transduction cascade, specifically by limiting the generation of the critical second messenger, cyclic AMP ( cAMP). This internal cellular mechanism modulates the pathway dynamics of the entire acid secretion process.


Resulting Peripheral Antisecretory Effect

This mechanistic domain reflects the system-level consequence of the molecular blockade. By suppressing the cAMP signal, Famotidine indirectly reduces the activity of the final acid-secreting enzyme, the H^+/ K^+-ATPase (Proton Pump). This action results in a pronounced antisecretory physiological effect, which is the marked decrease in both the volume and the acidity of the gastric secretions.

Dosage and Administration Information

Yamadin, a trade name for Famotidine, is administered via two primary routes based on the patient's clinical setting. The medication is primarily utilized via the oral route as a tablet or liquid suspension for both acute and maintenance therapy. An intravenous (IV) solution is formulated and generally reserved for short-term use in hospitalized patients who are temporarily unable to tolerate oral intake.

Dosing schedules vary according to the condition. For acute duodenal or gastric ulcer treatment, the standard adult regimen is 40 mg once daily at bedtime, or 20 mg twice daily. Maintenance therapy to reduce ulcer recurrence typically follows a 20 mg once daily schedule. For pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, the dose may be initiated at 20 mg every 6 hours and may be adjusted up to a maximum labeled dose of 160 mg every 6 hours.

Specific administration rules govern its intake. Oral forms can be taken with or without food. The liquid suspension must be shaken vigorously for 5 to 10 seconds prior to each measured dose. IV administration requires the injection to be delivered slowly, over a minimum of two minutes, or as an infusion over 15 to 30 minutes. A critical instruction for specific populations is the mandatory dose modification for patients with renal impairment: if creatinine clearance is below 50 mL/min, the dose must be reduced by 50% or the dosing interval extended to 36 to 48 hours to prevent accumulation.

Recent Clinical Evidence

Research evidence / Overview of studies for Yamadin

The research base for Yamadin (Famotidine) largely consists of historical, randomized controlled trials (RCTs) and controlled clinical studies. These studies explored the measurement of stomach acid output and how patient-reported outcomes and healing rates were observed in the studied populations. The evidence contributes to understanding the study parameters related to symptoms and ulcer healing, while also defining areas where data remain limited, such as long-term follow-up and specific populations.


Evidence for Healing Active Duodenal and Gastric Ulcers

The main research exploring the use of Yamadin for ulcers focused on short-term, placebo-controlled RCTs involving adults with confirmed active ulcers. These trials measured the endoscopically confirmed ulcer healing rate over defined periods, typically up to eight weeks. Trial reports described patterns related to the presence of endoscopically confirmed healing of the ulcer crater by the four-week and eight-week assessment points.

What remains uncertain is the applicability of these historical study results when compared to modern ulcer therapies, as much of the core evidence predates newer treatments. Also, since these were short-term studies, the long-term status of patients beyond the initial healing period is not fully documented.


Research on Preventing Ulcer Recurrence (Maintenance Therapy)

Research has explored the continued administration of Yamadin as a maintenance therapy following the successful healing of an active duodenal ulcer. These were intermediate-term, placebo-controlled studies that monitored adults over periods typically ranging from six to twelve months. Maintenance studies reported differences in the observed incidence of ulcer relapse between the group studied with Famotidine and the group studied with placebo over the studied year.

A key limitation is that these placebo-controlled maintenance studies have generally not been extended beyond one year, meaning there is limited information regarding outcomes related to ulcer recurrence beyond this intermediate time frame.


Evidence for Gastroesophageal Reflux Disease (GERD) and Esophagitis

For conditions related to acid reflux, research has explored the use of Yamadin in managing general GERD symptoms (non-erosive) and in exploring the healing of more severe erosive esophagitis. For symptomatic GERD, studies explored patient-reported outcomes describing perceived discomfort. For erosive esophagitis, reported healing rates in these historical trials were generally lower than those measured in studies involving more potent classes of acid-suppressing agents.

Frequently Asked Questions (FAQ)

Common questions about Yamadin (FAQ)


Q: How quickly does Yamadin start to work?

Official product information states that the medicine's action, which involves reducing stomach acid secretion, typically begins within one hour after it is taken orally. This is the time when the core antisecretory effect is described as starting.


Q: Does Yamadin make you feel sleepy or tired?

Regulatory documents mention side effects that relate to feeling less alert. Fatigue (tiredness) is listed as an uncommon side effect. The less common effect of somnolence (drowsiness) has also been reported. Additionally, feeling dizzy is a commonly reported side effect.


Q: How long do you typically need to take Yamadin?

The required duration of use is defined by the condition being treated. For active ulcers, treatment is often up to 8 weeks. For preventing ulcers from returning, studies have monitored patients for up to one year for maintenance therapy.


Q: Are there any foods or drinks I need to avoid while on Yamadin?

Regulatory information does not list specific food or drink restrictions due to absorption, and the medicine is typically permitted to be taken with or without food. Any specific restrictions on co-administration are generally limited to other medicines or specific antacid products.


Q: Is it safe to drive or operate machinery while taking Yamadin?

Because Yamadin may potentially cause side effects like dizziness, confusion, or hallucinations, official guidance notes that observing one's reaction to the medicine is important before driving or operating machinery. This is a common precaution for medicines that affect the central nervous system.


Q: Does Yamadin cause changes in mood or anxiety?

The official adverse reaction reports list several mental health effects as very rare, especially in certain patient groups. These include anxiety, depression, hallucinations, disorientation, and confusion.


Q: Can Yamadin be used during pregnancy, or while breastfeeding?

For pregnant women, use is recommended only if a clear need is established. For lactating women, official documents state that the active ingredient is excreted into human milk. The decision to continue or discontinue either nursing or the medicine is based on the professional assessment of need.


Q: Are there any genetic factors that affect how Yamadin works?

The primary mention related to a genetic factor concerns the liquid oral suspension. People with phenylketonuria (PKU) are advised to be aware that this suspension may contain aspartame, which is a source of phenylalanine. No other genetic factors are commonly cited in official warnings.


Q: Can Yamadin affect kidney function?

Yamadin is primarily eliminated from the body by the kidneys. For patients who already have impaired renal function (kidney problems), official guidance requires a mandatory dose adjustment. This is necessary to prevent the medicine from accumulating and potentially increasing the risk of central nervous system side effects.


Q: Does Yamadin cause weight gain or loss?

Weight changes are not listed among the commonly or uncommonly reported side effects. However, post-marketing reports have included mentions of both loss of appetite and unusual weight gain or loss in general adverse event listings.


Q: Does Yamadin cause dry mouth or changes in taste?

Regulatory information lists the side effect of a taste disorder as uncommon. Dry mouth is also mentioned in official documents as an uncommon adverse reaction.


Q: How does Yamadin affect the liver?

Regulatory documents indicate Yamadin has been associated with rare, documented instances of acute liver injury. Liver problems have been mentioned as a possible side effect in patient information, with outcomes often showing improvement when the medicine is stopped.


Q: Will Yamadin interfere with my ability to sleep?

The official adverse reaction list includes insomnia (trouble sleeping) as a very rare side effect. Other central nervous system effects such as agitation or confusion could also potentially interfere with rest or normal sleep patterns.


Q: Is Yamadin a newer or older medication?

The research base that supports Yamadin's use is described in official documents as relying on historical, randomized controlled trials. This indicates that the medicine has been in use for a substantial period.


Q: What types of drug-drug interactions are considered the most serious with Yamadin?

The most serious documented interactions are those where co-administration is officially advised against or not recommended. This is due to a risk of significantly altered exposure for one or both medicines. Examples include interactions with Probenecid and certain acid-dependent Tyrosine Kinase Inhibitors.


Q: Does Yamadin affect fertility?

Information regarding human fertility is limited, as official documents note there are no comparable adequate and well-controlled studies specifically on fertility in humans. Animal studies, however, have failed to reveal evidence of changes in fertility.

How should Yamadin be stored and disposed of?

Storage and Disposal of Famotidine (Yamadin)

Famotidine must be stored under specific, controlled conditions to maintain its effectiveness, as documented in official regulatory labeling.

Official Storage Requirements

The required storage environment is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be stored in its original container and kept tightly closed to provide necessary protection from light and moisture. The official labeling for the liquid oral suspension specifies the product must not freeze, and any remaining liquid must be discarded after 30 days of initial use. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. Patients are advised not to dispose of the medicine via wastewater unless specific instructions are provided on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yamadin found in:

A-Z Index: